UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Position in PHAT — Phathom Pharmaceuticals, Inc.

CIK 861177 NEW YORK, NY

Back to PHAT Full portfolio

Position in PHAT

as of Mar 31, 2026 · filed May 13, 2026 Compact

Position Value

$619,804

+$111,637 QoQ

Shares Held

55,788

+82.1% QoQ

Ownership

0.070%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2021

9 quarters on record

Voting authority Sole 28% Shared 0% None 72%

Common Shares in PHAT Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,287,605,811 across 211 Biotechnology names. PHAT ranks #139 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	3,057,396	$1,365,249,602
2	REGN	Regeneron Pharmaceuticals, Inc.	723,621	$559,098,523
3	ALNY	Alnylam Pharmaceuticals, Inc.	677,519	$224,170,706
4	INSM	INSMED Inc	1,215,025	$198,680,883
5	RPRX	Royalty Pharma plc	3,095,766	$148,503,890
6	INCY	Incyte Corp	1,540,913	$145,030,725
7	IONS	Ionis Pharmaceuticals Inc	1,475,632	$110,805,201
8	DNLI	Denali Therapeutics Inc.	4,432,314	$85,100,425

All Filings in PHAT

Export CSV

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$619,804	55,788	+82.1%	Shares	Defined	2026-05-13
2025-12-31	$508,167	30,631	-69.3%	Shares	Defined	2026-02-13
2025-03-31	$625,393	99,744	-15.3%	Shares	Defined	2025-05-19
2024-12-31	$956,558	117,803	+20.2%	Shares	Defined	2025-02-14
2024-09-30	$1,772,289	98,025	+5.2%	Shares	Defined	2024-11-14
2024-06-30	$959,483	93,154	+622.5%	Shares	Defined	2024-08-14
2024-03-31	$136,922	12,893	0.0%	Shares	Defined	2024-05-15
2023-12-31	$117,712	12,893	+71.6%	Shares	Defined	2024-02-14
2021-09-30	$241,198	7,514	—	Shares	Defined	2021-11-15
No filing history on record for this holder in this stock.